What is prognosis of Lung cancer?

Éist leis an leathanach seo

Cad é an réamhaisnéis maidir le ailse scamhóige?

Braitheann prognóis ailse scamhóige ar roinnt fachtóirí, lena n-áirítear céim an ailse, cineál an ailse scamhóige, agus sláinte foriomlán an othair.

Tá ráta maireachtála 5 bliana de thart ar 18% do na céimeanna go léir le chéile ag ailse scamhóige neamh-small cell, is é an cineál is coitianta.

Mar sin féin, má fhaightear an ailse go luath, is féidir leis an ráta maireachtála 5 bliana a bheith chomh hard le 57%. Tá ráta maireachtála 5 bliana ag ailse scamhóg cealla beaga, atá níos lú coitianta, d'amharc ar 7% do na céimeanna go léir le chéile.

Tá sé tábhachtach a thabhairt faoi deara gur staitisticí ginearálta iad seo agus d'fhéadfadh torthaí aonair a bheith éagsúil.

Leanann roghanna cóireála agus dul chun cinn sa leigheas ag feabhsú, agus is féidir le go leor othair maireachtáil níos faide agus cáilíocht bheatha níos fearr a bheith acu le cúram agus bainistíocht chuí.

Tagairtí

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Martini B: [Lung cancer--epidemiology, prognosis and therapy]. Med Monatsschr Pharm. 2006, 29 (6): 217-21.

Zou T, Liu JY, She L, Yin JY, Li X, Li XP, Zhou HH, Chen J, Liu ZQ: The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Pharmacol. 2020, 11 (): 1029.

Li L, Zhou Q, Luo D, Xu Y, Yang H, Zhang S, Li A, Li H, Lv C: [A study on the relationship between lung cancer cell apoptosis and prognosis in patients with human non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi. 1998, 1 (2): 70-3.

Feng YY, Yang Y, Wang YY, Bai XX, Hai P, Zhao R: [Hypomethylation of DAPL1 associated with prognosis of lung cancer patients with EGFR Del19 mutation]. Zhonghua Zhong Liu Za Zhi. 2021, 43 (12): 1264-1268.

Xiao Y, Zhu S, Yin W, Liu X, Hu Y: IGFBP-4 expression is adversely associated with lung cancer prognosis. Oncol Lett. 2017, 14 (6): 6876-6880.

Lang J, Zhao Q, He Y, Yu X: Bone turnover markers and novel biomarkers in lung cancer bone metastases. Biomarkers. 2018, 23 (6): 518-526.

Diúltú freagrachta: leighis

Cuirtear an suíomh gréasáin seo ar fáil chun críocha oideachais agus faisnéise amháin agus ní sholáthraíonn sé comhairle leighis nó seirbhísí gairmiúla.

Níor cheart an t-eolas a chuirtear ar fáil a úsáid chun fadhb sláinte nó galar a dhiagnóisiú nó a chóireáil, agus ba cheart dóibh siúd atá ag lorg comhairle leighis phearsanta dul i gcomhairle le dochtúir ceadúnaithe.

Tabhair faoi deara le do thoil go bhfuil an líonra néarónach a ghineann freagraí ar na ceisteanna, míchruinn go háirithe nuair a bhaineann sé le hábhar uimhriúil. Mar shampla, líon na ndaoine a ndearnadh diagnóis orthu le galar ar leith.

Déan comhairle do dhochtúir nó do sholáthraí sláinte cáilithe eile i gcónaí maidir le riocht leighis. Ná déan neamhaird ar chomhairle leighis ghairmiúil ná déileáil leis mar gheall ar rud éigin a léigh tú ar an suíomh Gréasáin seo. Má cheapann tú go bhféadfadh éigeandáil leighis a bheith agat, glaoigh ar 911 nó téigh go dtí an seomra éigeandála is gaire láithreach. Ní chruthaíonn an suíomh Gréasáin seo ná a úsáid aon chaidreamh dochtúir-othar. Ní dhéanann BioMedLib ná a chuid fostaithe, ná aon ranníocóir leis an suíomh Gréasáin seo aon ionadaíochtaí, sainráite nó intuigthe, maidir leis an bhfaisnéis a sholáthraítear anseo ná a úsáid.

Diúltú freagrachta: cóipchirt

Soláthraíonn an Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (an DMCA) aisíocaíocht do úinéirí cóipchirt a chreideann go sáraíonn ábhar atá le feiceáil ar an Idirlíon a gcearta faoi dhlí cóipchirt na Stát Aontaithe.

Má chreideann tú go dea-chreidimh go sáraíonn aon ábhar nó ábhar a chuirtear ar fáil i ndáil lenár suíomh Gréasáin nó lenár seirbhísí do chóipcheart, féadfaidh tú (nó do ghníomhaire) fógra a sheoladh chugainn ag iarraidh an t-ábhar nó an t-ábhar a bhaint, nó rochtain air a bhac.

Ní mór fógraí a sheoladh i scríbhinn trí ríomhphost (féach an rannán "Contact" le haghaidh seoladh ríomhphoist).

Éilíonn an DMCA go gcuimsíonn do fhógra faoi shárú cóipchirt líomhain an fhaisnéis seo a leanas: (1) cur síos ar an saothar cóipchirt atá ina ábhar don shárú líomhain; (2) cur síos ar an ábhar líomhain atá ag sárú líomhain agus faisnéis leordhóthanach chun ligean dúinn an t-ábhar a aimsiú; (3) faisnéis teagmhála duit, lena n-áirítear do sheoladh, uimhir theileafóin agus seoladh ríomhphoist; (4) ráiteas uait go bhfuil creideamh maith agat nach bhfuil an t-ábhar ar an mbealach a bhfuil gearán á dhéanamh air údaraithe ag úinéir cóipchirt, nó a ghníomhaire, nó ag oibriú aon dlí;

(5) ráiteas uait, arna shíniú faoi phionós perjury, go bhfuil an t-eolas sa fhógra cruinn agus go bhfuil an t-údarás agat na cóipchearta a éilítear a shárú a fhorfheidhmiú;

agus (6) síntiús fisiciúil nó leictreonach úinéir an chóipchirt nó duine údaraithe chun gníomhú thar ceann úinéir an chóipchirt.

D'fhéadfadh moill a bheith ar phróiseáil do ghearán mura gcuirfidh tú an t-eolas thuas go léir san áireamh.

Cumarsáid

Seol ríomhphost dúinn le haon cheist / moladh le do thoil.

What is prognosis of lung cancer?

The prognosis of lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the overall health of the patient.

Non-small cell lung cancer, which is the most common type, has a 5-year survival rate of about 18% for all stages combined.

However, if the cancer is caught early, the 5-year survival rate can be as high as 57%. Small cell lung cancer, which is less common, has a 5-year survival rate of about 7% for all stages combined.

It is important to note that these are general statistics and individual outcomes may vary.

Treatment options and advancements in medicine continue to improve, and many patients can live longer and have a better quality of life with proper care and management.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.